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ABSTRACT
Objective: To study the safety of off-label IV thrombolysis in patients with very severe stroke (NIH
Stroke Scale [NIHSS] scores .25) compared with severe stroke (NIHSS scores 15–25), where
treatment is within European regulations.
Methods: Data were analyzed from 57,247 patients with acute ischemic stroke receiving IV tis-
sue plasminogen activator in 793 hospitals participating in the Safe Implementation of Thrombol-
ysis in Stroke (SITS) International Stroke Thrombolysis Registry (2002–2013). Eight hundred
sixty-eight patients (1.5%) had NIHSS scores .25 and 19,995 (34.9%) had NIHSS scores 15–
25. Outcome measures were parenchymal hemorrhage, symptomatic intracerebral hemorrhage,
mortality, and functional outcome.
Results: Parenchymal hemorrhage occurred in 10.7% vs 11.0% (p 5 0.79), symptomatic intra-
cerebral hemorrhage per SITS-MOST (SITS–Monitoring Study) in 1.4% vs 2.5% (p 5 0.052),
death at 3 months in 50.4% vs 26.9% (p , 0.001), and functional independence at 3 months in
14.0% vs 29.0% (p , 0.001) of patients with NIHSS scores .25 and NIHSS scores 15–25,
respectively. Multivariate adjustment did not change findings from univariate comparisons. Pos-
terior circulation stroke was more common in patients with NIHSS scores .25 (36.2% vs 7.4%,
p , 0.001), who were also more often obtunded or comatose on presentation (58.4% vs 7.1%,
p , 0.001). Of patients with NIHSS scores .25, 26.2% were treated .3 hours from symptom
onset vs 14.5% with NIHSS scores of 15–25.
Conclusions: Our data show no excess risk of cerebral hemorrhage in patients with NIHSS score
.25 compared to score 15–25, suggesting that the European contraindication to IV tissue plas-
minogen activator treatment at NIHSS levels .25 may be unwarranted. Increased mortality and
lower rates of functional independence in patients with NIHSS score.25 are explained by higher
stroke severity, impaired consciousness on presentation due to posterior circulation ischemia,
and longer treatment delays. Neurology® 2015;85:1–9
GLOSSARY
aOR 5 adjusted odds ratio; ECASS II 5 European Cooperative Acute Stroke Study II; ICH 5 intracerebral hemorrhage;
IST-3 5 Third International Stroke Trial; mRS 5 modified Rankin Scale; NIHSS 5 NIH Stroke Scale; NINDS 5 National
Institute of Neurological Diseases and Stroke; PH 5 parenchymal hemorrhage; SICH 5 symptomatic intracerebral hemor-
rhage; SITS-ISTR 5 Safe Implementation of Thrombolysis in Stroke–International Stroke Thrombolysis Register; SITS-
MOST 5 Safe Implementation of Thrombolysis in Stroke–Monitoring Study; tPA 5 tissue plasminogen activator; VISTA 5
Virtual International Stroke Trials Archive.
Evidence has accumulated on treatment with IV thrombolysis for acute ischemic stroke in ini-
tially understudied patient groups: those older than 80 years, with a history of stroke and dia-
betes, and treated with anticoagulants.1–3 This is not yet the case for very severe stroke defined as
NIH Stroke Scale (NIHSS) scores above 25 points. Here, the European Medicines Agency
license for alteplase contraindicates treatment, stating: “patients with very severe stroke are at
higher risk for intracerebral hemorrhage (ICH) and death and should not be treated.”4 Formu-
lated in 2003, this was not based on high-grade evidence, as several trials at the time had
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excluded such patients.5,6 Later results from
the Virtual International Stroke Trials Archive
(VISTA) collaboration and the Third Interna-
tional Stroke Trial (IST-3) trial showed
improved outcomes in patients who received
thrombolysis with NIHSS scores $25,
although lacking statistical significance; nei-
ther study reported on ICH or symptomatic
ICH (SICH) in these patients.1,7
Increasing stroke severity is associated with
higher risk of SICH.8,9 During the develop-
ment of the SITS Risk Score, a predictive
instrument for thrombolysis-related SICH,10
we found indications that the risk may plateau
at high NIHSS levels. We hypothesized that
there may not be a significant increase in ICH
risk following thrombolysis in very severe
stroke defined as NIHSS scores.25 (off-label
in Europe), compared to severe stroke for
which treatment is within EU regulations,
i.e., NIHSS scores 15 to 25. The current study
aims to investigate this hypothesis and com-
pare clinical characteristics, mortality, causes
of death, and functional outcomes between
these patient groups.
METHODS Patients. All patients recorded in the SITS–Inter-
national Stroke Thrombolysis Register (SITS-ISTR) between
December 2002 and April 2013 treated with IV alteplase (Actilyse,
Boehringer-Ingelheim, Germany) were considered (n 5 58,293),
and only patients with available baseline NIHSS score were
included in this study (n 5 57,247; 98.2%). These were
enrolled at 793 centers in 44 countries, 95% in European hospitals.
The SITS-ISTR is an ongoing, prospective, academic-driven,
multinational register for centers using thrombolysis for the treat-
ment of acute ischemic stroke. The methodology of the SITS-
ISTR, including procedures for data collection and management,
patient identification, and verification of source data, has been
described previously.11,12 Consecutive case reporting is a basic
commitment for participating in the SITS-ISTR. We collected
baseline and demographic characteristics, stroke severity per the
standard 11-item, 42-point NIHSS, time logistics, medication
history, and imaging data on admission and follow-up.
We defined very severe stroke as baseline NIHSS scores higher
than 25 points and severe stroke as NIHSS scores 15 to 25. In total,
868 patients (1.5%) had very severe stroke, while 19,995 (34.9%)
had severe stroke. In October 2010, the SITS-ISTR implemented
the option to register information on the arterial territory affected
by the stroke. Territory data were available in 23.6% of all cases
with NIHSS scores 15–25 and .25 (total n 5 4,922/20,863).
Standard protocol approvals, registrations, and patient
consents. Ethics approval and patient consent for participation
in the SITS-ISTR were obtained in countries that required this;
other countries approved the register for anonymized audit.
The SITS International Coordination Office monitored the
SITS-ISTR data online and checked individual patient data
monthly to identify errors or inconsistencies.
Outcome measurements. The following definitions of cerebral
hemorrhage were used:
1. Any parenchymal hemorrhage (PH), local or remote, regard-
less of size or type (PH1, PHr1, PH2, PHr2) on any posttreat-
ment imaging scans during hospitalization.
2. PH type 2 (PH2) or remote (extraischemic) PH type 2 (PHr2)
on any posttreatment imaging scans during hospitalization.
“Type 2” indicates hematoma exceeding 30% of the infarct
(for PH2), with substantial space-occupying effect (both PH2
and PHr2).
3. SICH per SITS-MOST: PH2 or PHr2 on imaging 22 to 36
hours after treatment, or earlier if scanned because of clinical
deterioration, combined with a neurologic deterioration of$4
NIHSS points or leading to death within 24 hours.
4. SICH per European Cooperative Acute Stroke Study II
(ECASS II): any ICH on any posttreatment imaging after
the start of thrombolysis and increase of $4 NIHSS points
or leading to death, within 7 days.
5. SICH per National Institute of Neurological Diseases and
Stroke (NINDS): any ICH on any posttreatment imaging
and any deterioration in NIHSS or death within 7 days.
All SICH events were adjudicated centrally by the SITS Inter-
national Coordination Office based on submitted clinical and
imaging reports; images were not available for review.
Rates of mortality were assessed at 7 days and 3 months.
Functional outcome per the modified Rankin Scale (mRS) was
evaluated at 3 months. For patients deceased within 7 days and
3 months, we compared frequencies of various causes of death,
as well as the median time from treatment to death. All assess-
ments of imaging studies and neurologic and functional status
were done according to clinical routine at centers participating
in the SITS-ISTR.
Statistical analysis. We performed descriptive univariate statis-
tics for baseline clinical, demographic, and imaging data, as well
as outcomes, causes of death, and time to death, comparing pa-
tients with very severe (NIHSS .25) and severe (NIHSS 15–
25) stroke. For continuous and ordinal variables, median and
interquartile range values were calculated. For categorical varia-
bles, we calculated percentage proportions by dividing the num-
ber of events by the total number of patients, excluding missing or
unknown cases, as done in previous SITS publications.1,9 For
calculation of significance of difference between medians and
proportions, we used the Mann–Whitney U test and the Pearson
x2 method, respectively. For calculation of the 95% confidence
intervals of proportions for PH and SICH, the Wilson score
method with continuity correction was used.13 The association
between NIHSS and all hemorrhagic outcome definitions was
investigated graphically. We plotted the predicted probabilities
of the respective hemorrhagic outcomes against individual values
of the NIHSS. The fitted values were obtained from a univariate
logistic model in which NIHSS was included by means of a nat-
ural cubic spline. Computation was implemented using the
splines package in R, and the number of knots was selected based
on the Akaike Information Criterion. To investigate the relation-
ships between severe and very severe stroke and PH, SICH, func-
tional outcomes, and mortality, multivariate logistic regression
analyses were performed adjusting for factors known from
previous publications to be associated with these endpoints.
Specifically, analyses regarding all PH and SICH definitions were
adjusted for age, blood glucose, systolic blood pressure, onset-to-
treatment time, body weight, diabetes mellitus, hypertension, use
of aspirin, hyperdense cerebral artery sign, and visible infarct signs
on baseline CT.10,14 Analyses of mortality within 7 days and 3
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months and functional outcomes at 3 months were adjusted for all
factors listed above with the addition of atrial fibrillation, congestive
heart disease, and previous stroke.3,8 Analyses were performed using
STATISTICA 12 (StatSoft, Tulsa, OK) and R 3.1.1.
RESULTS Baseline characteristics of the studied
groups are shown in table 1. The very severe stroke
group had a higher median age, 75 vs 72 years, and
higher NIHSS scores, 28 vs 19 points. The proportion
of patients presenting in an obtunded or comatose
state, receiving 2 or 3 points on the 1A Level of Con-
sciousness subscale of the NIHSS was 58.4% in the
NIHSS .25 group compared to 7.1% in the NIHSS
15–25 group. Bilateral motor signs were present in
64.9% in the very severe and 7.8% in the severe stroke
group. Stroke in the posterior circulation occurred in
36.2% of patients with NIHSS .25, compared to
Table 1 Baseline characteristics in patients with very severe (NIHSS scores >25) and severe (NIHSS scores
15–25) stroke
Characteristic
NIHSS >25 (n 5 868) NIHSS 15–25 (n 5 19,995)
p ValueNo./total Median (IQR) or % No./total Median (IQR) or %
Age, y 867 75 (66–80) 19,980 72 (63–79) ,0.001
NIHSS baseline score 868 28 (26–31) 19,995 19 (16–21) ,0.001
BPsys pre-tPA 840 150 (133–166) 19,684 150 (135–165) 0.75
BPdia pre-tPA 840 80 (70–90) 19,680 80 (71–90) 0.21
Glucose, mmol/L 785 7.1 (6–8.6) 18,635 6.7 (5.8–8.1) ,0.001
Weight, kg 841 75 (66–85) 19,556 75 (66–85) 0.85
Actilyse, mg 857 67 (58–77) 19,897 67.5 (59–76) 0.15
ODT, min 776 72 (50–110) 18,923 67 (47–96) ,0.001
DNT, min 832 73 (50–109) 19,634 65 (46–90) ,0.001
OTT, min 829 150 (120–185) 19,783 140 (113–170) ,0.001
OTT >3 h 217/829 26.2 2,863/19,783 14.5 ,0.001
Obtunded or comatose 506/867 58.4 1,419/19,995 7.1 ,0.001
Women 429/868 49.4 9,405/19,995 47.0 0.17
Atrial fibrillation 274/840 32.6 6,166/19,527 31.6 0.52
Hypertension 597/844 70.7 13,153/19,621 67.0 0.025
Diabetes mellitus 188/835 22.5 3,583/19,693 18.2 0.002
Hyperlipidemia 270/779 34.7 6,073/18,252 33.3 0.42
Congestive heart failure 130/823 15.8 2,142/19,533 11.0 ,0.001
Previous stroke 141/842 16.7 2,398/19,648 12.2 ,0.001
Smoker, current 112/752 14.9 3,288/18,178 18.1 0.025
Smoker, previous 123/577 21.3 2,903/13,671 21.2 0.96
Aspirin 316/841 37.6 6,773/19,712 34.4 0.055
Clopidogrel 32/850 3.8 840/19,801 4.2 0.50
Warfarin, any INR 37/853 4.3 629/19,854 3.2 0.058
Statin 96/342 28.1 1,979/6,804 29.1 0.69
Early infarct signs 275/819 33.6 4,836/18,636 25.9 ,0.001
HCAS 333/813 41.0 6,655/18,630 35.7 0.002
Posterior circulation 80/221 36.2 347/4,701 7.4 ,0.001
Anterior circulation 141/221 63.8 4,354/4,701 92.6 ,0.001
Bilateral motor signs 563/867 64.9 1,568/19,994 7.8 ,0.001
Unilateral motor signs 304/867 35.1 18,426/19,994 92.2 ,0.001
Abbreviations: BPdia 5 diastolic blood pressure; BPsys 5 systolic blood pressure; DNT 5 door-to-needle time; HCAS 5
hyperdense cerebral artery sign; INR 5 international normalized ratio; NIHSS 5 NIH Stroke Scale; ODT 5 onset-to-door
time; OTT 5 onset-to-treatment time; tPA 5 tissue plasminogen activator.
Continuous variables presented as median (interquartile range [IQR]) and p values per Mann–Whitney U test. Categorical
variables presented as percentages and p values per Pearson x2 test. Obtunded or comatose 5 2 or 3 points on NIHSS
item 1A, Level of Consciousness.
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7.4% in NIHSS 15–25. Patients with NIHSS scores
.25 were treated later, with an onset-to-treatment
time of 150 vs 140 minutes, and a longer door-to-
needle time of 73 vs 65 minutes. CT was used as the
initial imaging modality in 97.2% of cases. Early
infarct signs on baseline imaging scans were observed
in 33.6% of patients in the NIHSS .25 group and
25.9% in the NIHSS 15–25 group, while the
hyperdense cerebral artery sign was seen in 41.0% vs
35.7%. The groups were similar regarding sex, blood
pressure, body weight, and total alteplase dose,
diagnoses of atrial fibrillation and hypertension, as
well as baseline treatment with antiplatelet,
anticoagulant, and cholesterol-lowering drugs. A total
of 29 of 868 patients (3.3%) with NIHSS score .25
and 308 of 19,995 patients (1.5%) with NIHSS score
15–25 were recorded as treated with endovascular
thrombectomy after IV thrombolysis.
PH of any type or size occurred in 10.7% of pa-
tients with NIHSS score .25 and 11.0% with
NIHSS score 15–25. Large PH with significant mass
effect (PH2 or PHr2) was seen in 3.7% and 5.1% of
patients with NIHSS .25 and NIHSS 15–25,
respectively. Differences in the occurrence of SICH
were small (table 2): SITS-MOST 1.4% vs 2.4%,
ECASS II 10.8% vs 8.7%, and NINDS 13.2% vs
11.4%. Figure 1 illustrates the distribution of PH
and SICH across the entire stratified range of the
NIHSS. Graphical trends of the association between
unadjusted baseline NIHSS score treated as a
continuous variable and PH and SICH rates are
shown in figure 2.
Multivariate analysis adjusting for differences in
known risk factors for PH and SICH between pa-
tients with NIHSS scores .25 and NIHSS scores
15–25 confirmed the findings from univariate com-
parisons (table 2). Following adjustment, there were
no statistically significant differences in risk for any
PH or SICH between the 2 severity strata, while the
adjusted odds ratio (aOR) for PH2/PHr2 was actually
lower in the NIHSS.25 group compared to NIHSS
15–25. In an additional multivariate analysis includ-
ing only patients with NIHSS above 25, the well-
established independent association of stroke severity
with PH and SICH reported in numerous previous
publications was no longer observed.
Because of limited numbers of patients with
known stroke territory, we investigated the associa-
tion of territory and PH/SICH using a simplified
multivariate logistic regression model including strat-
ified NIHSS (15–25 and .25), stroke territory, age,
baseline blood glucose, systolic blood pressure, and
aspirin. This included 152 patients with NIHSS.25
and 3,602 with NIHSS 15–25. Here, posterior cir-
culation stroke was negatively associated with PH/
SICH: with aOR 0.4 (0.1–0.6, p, 0.001) for SICH
NINDS, aOR 0.5 (0.3–0.8, p 5 0.008) for SICH
ECASS II, aOR 0.6 (0.1–1.0, p 5 0.22) for
SICH SITS-MOST, aOR 0.7 (0.5–0.9, p 5 0.064)
for any PH/PHr, and aOR 0.64 (0.3–0.9, p 5 0.14)
Table 2 Outcomes by stroke severity group, unadjusted and adjusted analysis
Outcome NIHSS >25, no./total (%) NIHSS 15–25, no./total (%) p Value NIHSS >25, aOR p Value
Any PH or PHr 82/768 (10.7) 2,093/19,043 (11.0) 0.79 0.9 (0.7–1.0) 0.34
PH2 or PHr2 28/768 (3.7) 970/19,043 (5.1) 0.072 0.6 (0.4–0.8) 0.042
SICH SITS-MOST 11/783 (1.4) 480/19,205 (2.5) 0.052 0.7 (0.4–1.0) 0.25
SICH ECASS II 82/758 (10.8) 1,624/18,657 (8.7) 0.044 1.0 (0.9–1.2) 0.88
SICH NINDS 101/763 (13.2) 2,140/18,728 (11.4) 0.12 1.0 (0.9–1.1) 0.99
Dead 7 d 237/803 (29.5) 2,430/19,126 (12.7) ,0.001 2.4 (2.3–2.5) ,0.001
Dead 3 mo 358/711 (50.4) 4,302/15,978 (26.9) ,0.001 2.3 (2.2–2.4) ,0.001
mRS score
0–1 58/705 (8.2) 2,687/15,760 (17.0) ,0.001 0.5 (0.4–0.7) ,0.001
0–2 99/705 (14.0) 4,578/15,760 (29.0) ,0.001 0.5 (0.4–0.6) ,0.001
0–3 165/705 (23.4) 6,997/15,760 (44.4) ,0.001 0.5 (0.4–0.6) ,0.001
Abbreviations: aOR 5 adjusted odds ratio; ECASS II 5 European Cooperative Acute Stroke Study II; mRS 5 modified
Rankin Scale; NIHSS5 NIH Stroke Scale; NINDS5 National Institute of Neurological Diseases and Stroke; PH or PHr5 any
parenchymal hemorrhage, local or remote, on any scan within 22–36 hours from treatment; PH2 or PHr2 5 local or remote
parenchymal hemorrhage type 2; SICH 5 symptomatic intracerebral hemorrhage; SITS-MOST 5 Safe Implementation of
Thrombolysis in Stroke–Monitoring Study.
Percentages and p values are per the Pearson x2 test, except the analysis of time to death, where medians (interquartile
ranges) are compared using the Mann–Whitney U test. aORs for intracerebral hemorrhage and SICH are adjusted for age,
onset-to-treatment time, blood glucose, systolic blood pressure, body weight, hypertension, diabetes mellitus, use of
aspirin, visible infarct signs on baseline imaging, and baseline hyperdense cerebral artery sign. aORs for mRS and mortality
are adjusted for all the above, plus atrial fibrillation, congestive heart failure, and previous stroke.
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for PH2/PHr2. In this analysis, NIHSS .25 re-
mained without an independent association with all
PH/SICH definitions, similar to results from the full
multivariate model (table 2).
Among patients who died within 7 days and 3
months, ICH was reported to be the cause of death
less frequently in the NIHSS .25 group compared
to the NIHSS 15–25 group (table 3). There was no
significant difference in the combined cause of death
“cerebral infarct and hemorrhage without specifica-
tion” between the groups.
Mortality at 7 days (29.5% vs 12.7%) and 3
months (50.4% vs 26.9%) was higher in the NIHSS
.25 group, while proportions of patients with excel-
lent (mRS 0–1), functionally independent (mRS
0–2), and favorable (mRS 0–3) outcome at 3 months
were lower compared to the NIHSS 15–25 group
(table 2). Figure e-1 on the Neurology® Web site at
Neurology.org shows functional outcomes and mor-
tality across all stroke severity levels. In deceased pa-
tients with a reported time of death, survival time was
shorter in the very severe stroke group: 3.8 days vs 6.1
days in NIHSS 15–25. Following multivariate adjust-
ment, stroke severity above NIHSS 25 remained
independently associated with higher short- and
long-term mortality, and worse functional
outcomes compared to NIHSS 15–25 (table 2).
DISCUSSION We report a large observational study
of outcomes following IV tissue plasminogen
activator (tPA) treatment for very severe and severe
stroke, and present results on treatment safety in pa-
tients with NIHSS score.25, in whom IV thrombol-
ysis is currently off-label in Europe. Our main finding
is that ICH risk is not increased following IV tPA
treatment in patients with very severe stroke (NIHSS
scores .25) compared to severe stroke (NIHSS scores
15–25). At high stroke severity, there is no further
increase in ICH or SICH rates beyond NIHSS levels
of 20–25, and the well-established relationship
between increasing stroke severity and cerebral
hemorrhagic complications is no longer seen beyond
the NIHSS level of 25 points in multivariate analysis.
Although mortality is higher in the NIHSS .25
group, it is not explained by an excess of
hemorrhagic complications. The increased mortality
in patients with NIHSS .25 is largely explained by
the higher stroke severity itself, reflected by many
patients with a decreased consciousness level at
presentation. Patients with very severe stroke are also
older and have more comorbidities such as congestive
heart failure, previous stroke, and diabetes (table 1).
The lack of increase in cerebral hemorrhagic com-
plications in the NIHSS .25 group is reflected by
our finding that ICH, alone or together with the
infarct, is not more often the cause of death within
7 days and 3 months than in patients with lower
severity stroke.
Previous studies have demonstrated that time
from stroke symptom onset to IV tPA treatment
Figure 1 Frequency of PH and symptomatic intracerebral hemorrhage by stroke severity
PH/PHr: any parenchymal hemorrhage, local or remote on any posttreatment scan during hospitalization. PH2/PHr2: Local
or remote parenchymal hemorrhage type 2 on any posttreatment scan during hospitalization. “Type 2” indicates hematoma
exceeding 30% of the infarct (for PH2), with substantial space-occupying effect (both PH2 and PHr2). ECASS II 5 Euro-
pean Cooperative Acute Stroke Study II; NINDS 5 National Institute of Neurological Diseases and Stroke; SITS-MOST 5
Safe Implementation of Thrombolysis in Stroke–Monitoring Study.
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decreases with increasing stroke severity.15,16 Our
findings show that this relationship is inverted at
the upper extreme of stroke severity. More patients
with NIHSS scores.25 were treated beyond 3 hours
from symptom onset, compared to NIHSS scores 15–
25 (26% vs 14%). This could be explained by more
patients with very severe stroke presenting obtunded
or comatose, increasing the complexity of initial diag-
nosis and management. In the NIHSS .25 group,
the reduced level of consciousness and the high pro-
portion of bilateral motor signs is in keeping with
more posterior circulation strokes in this group com-
pared to the NIHSS 15–25 group.
The differences in affected vascular territory are
important for the interpretation of our results on SICH.
In adjusted analysis, posterior territory stroke is associ-
ated with a lower risk of SICH per NINDS and
ECASS, with nonsignificant trends in the same direc-
tion for all other hemorrhage definitions. Lower risk
of hemorrhagic transformation and SICH in posterior
circulation infarcts has previously been reported in
patient cohorts who did and did not receive thrombol-
ysis.17–19 The frequent occurrence of posterior circula-
tion infarcts in patients with NIHSS score .25 is an
important explanation for the lack of increase in ICH
and SICH despite the higher stroke severity, which is
otherwise strongly associated with the risk of ICH and
SICH.8–10 Table e-1 shows that hemorrhagic complica-
tions are consistently less common in patients with pos-
terior circulation stroke in both severity groups. Poor
functional outcomes and high mortality in the NIHSS
.25 group also reflect the higher proportion of major
posterior circulation stroke, i.e., basilar artery occlusion.
Among patients with basilar artery occlusion and very
severe neurologic deficits treated with IV tPA in the
BASICS (Basilar Artery International Cooperation
Study) trial, only 26% achieved mRS score of 0 to 3
and 50% were dead at 1 month of follow-up, similar to
23% with mRS score of 0 to 3 and 50% dead at 3
months in the NIHSS .25 group in our study.20
Figure 2 Relationship between baseline NIHSS score and risk of ICH/SICH following stroke thrombolysis
(A) Any PH/Phr (%), (B) SICH SITS-MOST (%), (C) SICH ECASS II (%), and (D) SICH NINDS (%). Black line indicates risk of the
respective hemorrhagic outcome; red lines indicate 95% confidence intervals. The graph was produced using univariate
logistic regression, with NIHSS included by means of a natural cubic spline. ECASS II5 European Cooperative Acute Stroke
Study II; ICH 5 intracerebral hemorrhage; NIHSS 5 NIH Stroke Scale; NINDS 5 National Institute of Neurological Diseases
and Stroke; PH5 parenchymal hemorrhage; SICH5 symptomatic ICH; SITS-MOST5 Safe Implementation of Thrombolysis
in Stroke–Monitoring Study.
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At 1.5%, the proportion of patients with NIHSS
score .25 in our study is lower than in previous IV
thrombolysis publications from the IST-3 trialists and
the VISTA trial data repository (2.9% and 4.2% with
NIHSS scores $25, respectively).1,7 This could
reflect a reluctance of physicians in routine practice,
especially in Europe, to offer off-label treatment with
IV tPA to patients with NIHSS score .25 outside
clinical trials.
It is important to address the difficulty in estab-
lishing clinical deterioration in patients receiving
thrombolysis with baseline NIHSS score .25
who subsequently have an ICH discovered on
scheduled follow-up imaging at 22 to 36 hours.
This may affect the calculation of SICH rates in
this group. To compensate for this, we report 2
purely radiologic ICH definitions: any PH and
PH type 2. Figures 1 and 2 show consistency
between patterns of radiologic definitions of ICH
and clinicoradiologic definitions of SICH across
stroke severity strata.
Our study has several limitations. In 18% and
19% of patients, 3-month follow-up data for mortal-
ity and functional outcome are lacking. We attempt
to mitigate the missing data for death within 3
months by including 7-day mortality rates, where re-
cords are 95% complete. Furthermore, the stroke
territory variable, i.e., anterior or posterior circula-
tion, was implemented in SITS-ISTR in 2010. To
check for potential reporting bias, we performed a
sensitivity analysis comparing outcomes in patients
with and without territory data. Reassuringly, rates
of PH, SICH, death, and functional outcomes were
well-matched between the 2 groups (table e-2), indi-
cating that patients with available territory data are
representative of the registry. Until 2010, the SITS-
ISTR lacked input possibilities for endovascular
stroke treatment, and it was not widely practiced in
Europe. Endovascular thrombectomy following IV
tPA was uncommon in our material, registered in
1.6% of all patients. We believe this fraction is
unlikely to have influenced our results.
There are important parallels between regula-
tions surrounding IV thrombolysis for very severe
stroke and those previously applied to treatment of
patients older than 80 years, until recently contrain-
dicated for similar safety reasons. Outcomes are
inevitably poorer among the elderly as in those with
very severe stroke. This has been conflated with a
presumption of poorer response to treatment. Evi-
dence undermining and eventually disproving that
fear regarding the elderly has gradually accumu-
lated.1,21,22 Meantime, thousands of elderly patients
were denied effective treatment. Our results indicate
that the same situation likely exists for very severe
stroke.
Our findings suggest that the European label
contraindication to IV thrombolysis treatment in
patients with NIHSS score .25 based on safety
concerns may be unwarranted. We found no excess
risk of cerebral hemorrhage in this group compared
to patients receiving thrombolysis for severe stroke
with NIHSS score 15–25. Our findings are rein-
forced by the recent individual patient data meta-
analysis by the Stroke Thrombolysis Trialists’
Collaboration, showing a clear positive treatment
effect of IV tPA in severe stroke, despite the increase
in SICH inherent to thrombolytic therapy.22 Of
note, patients with NIHSS score .25 frequently
present with a reduced level of consciousness and
receive thrombolysis with a longer delay than others,
which contributes to poor functional outcomes and
high mortality. Recent major studies have shown
that endovascular thrombectomy in addition to IV
tPA strongly improves the prognosis in severe large
artery occlusion stroke. In light of this new evidence,
efforts should be made to increase and accelerate the
delivery of IV thrombolysis and thrombectomy for
the most severely afflicted stroke patients. This study
provides Class III evidence that treatment with IV
thrombolysis in patients with NIHSS scores .25
holds no excess risk compared to patients with
NIHSS scores 15–25.
Table 3 Causes of death in patients with NIHSS scores >25 and 15–25
NIHSS >25 NIHSS 15–25 p Value
Cause of death within 7 d n 5 198 n 5 2,051
Cerebral infarct 143 (72.2) 1,206 (58.8) ,0.001
Cerebral hemorrhage 8 (4.0) 205 (10.0) 0.006
Infarct and hemorrhage 18 (9.1) 284 (13.9) 0.061
Myocardial infarction 5 (2.5) 66 (3.2) 0.59
Pneumonia 6 (3.0) 113 (5.5) 0.14
PE/DVT 4 (2.0) 30 (1.5) 0.54
Other 8 (4.0) 89 (4.3) 0.84
Unknown 6 (3.0) 58 (2.8) 0.87
Cause of death within 3 mo n 5 289 n 5 3,509
Cerebral infarct 185 (64.0) 1,653 (47.1) ,0.001
Cerebral hemorrhage 9 (3.1) 261 (7.4) 0.006
Infarct and hemorrhage 24 (8.3) 360 (10.3) 0.29
Myocardial infarction 8 (2.8) 124 (3.5) 0.49
Pneumonia 34 (11.8) 490 (14.0) 0.30
PE/DVT 6 (2.1) 93 (2.7) 0.56
Other 16 (5.5) 360 (10.3) 0.001
Unknown 7 (2.4) 168 (4.8) ,0.001
Abbreviations: DVT 5 deep vein thrombosis; PE 5 pulmonary embolism.
Data represent n (%). Percentages and p values are per the Pearson x2 test. Total number in
both stroke severity groups comprises patients known to be dead at the respective follow-
up time points, with available cause of death data. The p values per Pearson x2 test.
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